Allogene Therapeutics, Inc.’s ALLO share price has surged by 6.64%, which has investors questioning if this is right time to ...

Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational ...

March 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) products for ...

Equities research analysts at Zacks Research issued their Q1 2027 earnings per share estimates for Allogene Therapeutics in a ...

Allogene Therapeutics ALLO incurred a loss of 28 cents per share in fourth-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents. In the year-ago period, the company had ...

Hello. Thank you for standing by, and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions] Please be aware that, today's conference call is ...

Allogene Therapeutics (ALLO) announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...